Ultragenyx Pharmaceutical Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 16.78 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.65B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Details
| Name | Ultragenyx Pharmaceutical Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 1371 |
| Founded | 2010 |
| Ipo Date | 2014-01-31 |
| Ceo | Emil Kakkis |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US90400D1081 |
| Cusip | 90400D108 |
| Cik | 0001515673 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, Chief Executive Officer and Director |
| Howard Horn | Executive Vice President of Corporate Strategy and Chief Financial Officer |
| Karah Herdman Parschauer J.D. | Chief Legal Officer and Executive Vice President of Corporate Affairs |
| Erik Harris M.B.A. | Executive Vice President and Chief Commercial Officer |
| Dr. Eric Crombez M.D. | Chief Medical Officer and Executive Vice President |
| Theodore A. Huizenga | Senior Vice President, Corporate Controller and Principal Accounting Officer |
| Ernie W. Meyer | Chief Human Resources Officer and Executive Vice President |
| Vimal Srivastava | Senior Vice President of Business Development and Alliance Management |
| Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations |
| John Richard Pinion II | Chief Quality Operations Officer and Executive Vice President of Translational Sciences |
Contact
| Address | 60 Leveroni Court, Novato, California 94949, United States |
| Phone | 415 483 8800 |
| Website | https://www.ultragenyx.com |